Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Birrer

Showing results (141-150 of 222) with videos related to

Pageof 23
Sort By:
Cancer|April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsKathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Gynecologic Oncology|December 29, 2016
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group studyCarolyn K McCourt, Wei Deng, Don S Dizon, et al.
Nature Communications|October 4, 2014
Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potentialCecilia S Leung, Tsz-Lun Yeung, Kay-Pong Yip, et al.
Cancer Biology & Therapy|July 26, 2011
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinomaAndrea R Hagemann, Ian S Hagemann, Mark Cadungog, et al.
Gynecologic Oncology|March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized studyKrishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
Gynecologic Oncology Reports|January 15, 2020
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Gynecologic Oncology|June 15, 2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancerKathleen N Moore, Michael J Birrer, Jim Marsters, et al.
Cancers|March 28, 2020
Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor MicroenvironmentWhitney N Goldsberry, Selene Meza-Perez, Angelina I Londoño, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)Diane M Da Silva, Danielle M Enserro, Jyoti S Mayadev, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 5, 2021
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot StudyTatyana A Grushko, Virginia L Filiaci, Anthony G Montag, et al.
Pageof 23

Showing results (141-150 of 222) with videos related to

Sort By:
Pageof 23
Cancer|April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsKathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Gynecologic Oncology|December 29, 2016
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group studyCarolyn K McCourt, Wei Deng, Don S Dizon, et al.
Nature Communications|October 4, 2014
Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potentialCecilia S Leung, Tsz-Lun Yeung, Kay-Pong Yip, et al.
Cancer Biology & Therapy|July 26, 2011
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinomaAndrea R Hagemann, Ian S Hagemann, Mark Cadungog, et al.
Gynecologic Oncology|March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized studyKrishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
Gynecologic Oncology Reports|January 15, 2020
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Gynecologic Oncology|June 15, 2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancerKathleen N Moore, Michael J Birrer, Jim Marsters, et al.
Cancers|March 28, 2020
Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor MicroenvironmentWhitney N Goldsberry, Selene Meza-Perez, Angelina I Londoño, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)Diane M Da Silva, Danielle M Enserro, Jyoti S Mayadev, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 5, 2021
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot StudyTatyana A Grushko, Virginia L Filiaci, Anthony G Montag, et al.
Pageof 23